Roivant Sciences (ROIV) Q1 2025 earnings summary

Executive summary

• Achieved net income of $57.5M for the quarter ended June 30, 2024, reversing a prior year net loss, driven by a $110M Telavant milestone and strong VTAMA sales.

• VTAMA net product revenue reached $18.4M, with over 430,000 prescriptions written and broad US commercial coverage.

• Completed enrollment in key Phase 3 trials for batoclimab (MG), brepocitinib (DM), and advanced brepocitinib to Phase 3 in NIU.

• Ended the quarter with $5.7B in cash and equivalents, following a $648M share repurchase.

• Significant pipeline progress with multiple late-stage registrational trials and upcoming clinical milestones.

Financial highlights

• Net income of $57.5M and net revenues of $55.1M for the quarter, including $18.4M from VTAMA and $36.8M in license/milestone revenue.

• R&D expenses increased to $133.2M, with non-GAAP R&D at $121.5M; SG&A expenses decreased to $148.5M, with non-GAAP SG&A at $107.5M.

• Cash, cash equivalents, and restricted cash totaled $5.7B at quarter-end.

• Debt included a $38M credit facility and $198M VTAMA royalty financing; renegotiated Dermavant's debt, reducing future obligations.

• Basic EPS was $0.13 for the quarter.

Outlook and guidance

• Expect FDA PDUFA action for VTAMA in atopic dermatitis in Q4 2024.

• Multiple clinical trial readouts and milestones anticipated by March 31, 2025, including IMVT-1402, batoclimab, and brepocitinib data.

• Immunovant aims to initiate 4–5 registrational programs for IMVT-1402 by fiscal year-end, expanding to 10 indications next fiscal year.

• Kinevant to report topline Phase 2 data for namilumab in sarcoidosis in Q4 2024.

• Management expects existing cash to fund operations and capital expenditures for at least the next 12 months.